The Future of Biosimilars

L El-Bakry

DOI: http://dx.doi.org/10.5138/09750215.1930

Abstract


Biosimilars are to Biologic products what generic drugs are to chemical products, a more affordable solution to the increasing drug pricing without sacrificing the quality of the treatment.There is much debate in the health care industry as to whether Biosimilars will deliver on the same success achieved by the generic products, which can amount to up to 80% in some cases.   It is my view though that Biosimilars provide a viable path to cost reduction, quality improvement and affordable accessibility to medication.  In fact, the introduction of lower costs Biologics as intended by the Biosimilar market will force competition within the therapeutics treatment market that will both exertpricing pressure as well as inspire innovation in the entire ecosystem. 


Keywords


Biosimilars; generic drugs; quality improvement; ecosystem; BPCI Act.

Full Text:

PDF

Refbacks

  • There are currently no refbacks.




Copyright (c) 2017 L. El-Bakry

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Advanced Research Journals

18K, Street 1st, Gaytri Vihar, Pinto Park, Gwalior, M.P. India

Copyright@arjournals.org (Design) 2009-2016

 

Follow @arjournals on Twitter